ENTITY
BioDlink International

BioDlink International (1875 HK)

74
Analysis
Health Care • China
Develops, manufactures and markets anti-tumor drugs
more
•05 Jan 2021 09:51

Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape

This article summarized the insights on major products of Bio-Thera Solutions in the pipeline and related competitive landscape with other key...

Logo
548 Views
Share
bullish•Everest Medicines
•24 Oct 2020 23:47

What HKEX Biotech "Step-Ups" Can Tell Us

This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...

Share
•13 Sep 2019 09:31

TOT Biopharm (äøœę›œčÆäøš) IPO: Valuation of Core Product TAB008, a Bevacizumab Biosimilar

TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing in its Hong Kong...

Logo
1.1k Views
Share
bullish•AllHome Corp
•07 Sep 2019 14:15

ECM Weekly (7 Sep 2019) - China Merchants Comm REIT, Immunotech Bio, Bank of Guizhou, XD, Huize

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
•12 Jul 2019 09:53

TOT Biopharm (äøœę›œčÆäøš) IPO: An Unimpressive Pipeline

TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing on the Hong Kong...

Logo
1.2k Views
Share
x